Biomarkers and kidney decline in pulmonary hypertension
Part of Heart & circulation, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at how certain blood markers (biomarkers) relate to kidney function decline in people with pulmonary hypertension. Participants will have blood and urine tests, and their kidney function will be tracked over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be an inpatient (currently in the hospital).
- You must be scheduled for a right heart catheterization.
- You must not have active cancer requiring treatment.
- You must not have an autoimmune or inflammatory disease affecting the kidneys that requires immunosuppressive treatment.
- You must not have had a sudden decline in kidney function in the past week.
- You must not have advanced chronic kidney disease (eGFR less than 20).
- You must not have had certain treatments (like dialysis or ultrafiltration) for fluid overload not related to kidney failure.
- You must not have received NSAIDs (like ibuprofen) or IV contrast within 72 hours before the heart catheterization.
- You must not have certain kidney conditions (such as polycystic kidney disease, glomerulonephritis, or a single kidney).
- You must not have had a kidney or other organ transplant.
- Your life expectancy must be at least 12 months.
- You must not be expected to need advanced therapies (like a mechanical heart pump or lung transplant) soon.
- You must not be pregnant or planning to become pregnant within the next year.
- You must be able to cooperate with breathing instructions during a kidney ultrasound (Doppler).
- You must be willing to participate and be available for follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to measure the blood pressure in the lungs of people who have chronic kidney disease. It uses both non-invasive (like ultrasound) and invasive (with a tube) methods to find out if they have high blood pressure in the lungs.
This study tests a new approach to protect the heart and kidneys in people with both chronic kidney disease and heart or blood vessel problems. By optimising treatment, researchers hope to reduce the risk of further kidney or heart damage.
This study is tracking people with pulmonary hypertension (high blood pressure in the lungs) over time to see how their condition and quality of life change. By joining, you help doctors better understand the disease and improve care for others like you.
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
This observational study is looking at people diagnosed with pulmonary hypertension to better understand how it behaves over time. You may help researchers by allowing repeated check-ins for years and sharing symptom and test information.
This study is testing whether a new risk score can better predict outcomes for people who have both chronic lung disease and pulmonary hypertension (high blood pressure in the lungs). If you qualify, the researchers will follow your health over time to see how well the score works.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.